Boston Scientific (NYSE:BSX) Cut to “Hold” at Wall Street Zen

Boston Scientific (NYSE:BSX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other brokerages also recently commented on BSX. TD Cowen decreased their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Truist Financial cut their price objective on Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Morgan Stanley reduced their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Wells Fargo & Company decreased their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Citigroup lowered their target price on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Stock Down 1.4%

BSX opened at $69.21 on Friday. Boston Scientific has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The firm has a market capitalization of $102.86 billion, a P/E ratio of 35.68, a PEG ratio of 1.08 and a beta of 0.69. The company’s 50-day moving average is $77.45 and its 200 day moving average is $90.83. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Laurel Wealth Advisors LLC raised its position in shares of Boston Scientific by 25,858.3% in the second quarter. Laurel Wealth Advisors LLC now owns 3,115 shares of the medical equipment provider’s stock valued at $335,000 after purchasing an additional 3,103 shares during the period. Scotia Capital Inc. lifted its stake in shares of Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Boston Scientific by 107.9% during the 2nd quarter. Mackenzie Financial Corp now owns 1,603,611 shares of the medical equipment provider’s stock valued at $172,244,000 after buying an additional 832,272 shares in the last quarter. Finally, Edgewood Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $746,655,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.